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Cobalamin C (cblC) defect is an inherited autosomal recessive disorder that affects cobalamin metabolism. Pa-
tients are treated with hydroxycobalamin to ameliorate the clinical features of early-onset disease and prevent
clinical symptoms in late-onset disease. Here we describe a patient in whom prenatal maternal treatment with
30 mg/week hydroxycobalamin and 5 mg/day folic acid fromweek 15 of pregnancy prevented disease manifes-
tation in a girl who is now 11 years oldwith normal IQ and onlymild ophthalmic ﬁndings. The affected older sis-
ter received postnatal treatment only and is severely intellectually disabled with severe ophthalmic symptoms.
This case highlights the potential of early, high-dose intrauterine treatment in a fetus affected by the cblC defect.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Cobalamin C (cblC) defect is the most common disorder that affects
intracellular cobalamin metabolism. The conversion of dietary cobala-
min into its two metabolically active forms, adenosylcobalamin and
methylcobalamin is impaired, resulting in elevated homocysteine
(Hcy) andmethylmalonic acid concentrations in body ﬂuids [1]. A num-
ber ofmutations in theMMACHC gene have been characterised resulting
in symptomatic cblC defect, which is inherited in an autosomal reces-
sive manner [2]. Clinical features comprise failure to thrive, mental re-
tardation, visual impairment, hydrocephalus and congenital cardiac
anomalies. Early treatment with hydroxycobalamin (OHCbl), betaine
and folate has a positive impact on survival and severe organ damage.
However, visual impairment and neurocognitive disability can rarely
be prevented in early-onset disease [1]. Here we report a favourable
outcome in the younger of two affected female siblings following prena-
tal treatmentwith 30mg/week OHCbl fromweek 15 of pregnancy until
delivery.
2. Patients and methods
Biochemical and enzymatic prenatal diagnosis was performed at
15 weeks of gestation during the second pregnancy of a woman who
had two years previously given birth to a female child (sibling 1) with
severe early-onset cblC defect. This child exhibitsmultiple developmen-
tal problems despite treatment with OHCbl, betaine and folic acid from
week 4 of life [4]. She is now 16 years of age, unable to walk and to
speak, and has severe visual impairment and behavioural problems.
The parents are of Caucasian origin, no consanguinity. She has one
older non-affected sibling.
Following conﬁrmation of cblC defect in the fetus during the second
pregnancy, the mother was treated from week 15 of gestation with in-
tramuscular OHCbl (3 × 10mg/week) and folic acid (5mg/day) after in-
formation that this treatment was an individual treatment attempt.
Postnatal treatment of sibling 2 consisted of oral betaine
200 mg/kg BW/day, folic acid 5 mg/day and intramuscular OHCbl
1 mg/day. At last follow-up at the age of 11 years, the child was treated
with 2 × 10 mg intramuscular OHCbl per week, oral betaine
180 mg/kg/day and folic acid 5 mg/day (Table 1c).
Biochemical analyses of serum total Hcy (tHcy), propionylcarnitine
and methylmalonic acid in urine were performed by tandem MS and
HPLC/MS/MS respectively (Zentrum für Stoffwechseldiagnostik Reut-
lingen GmbH, Reutlingen, Germany). Enzymatic assessment and muta-
tional analysis of the MMACHC gene were performed as described
elsewhere [3] (Fig. 1).
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3. Results
Biochemical and clinical ﬁndings are summarised in Table 1a–c. No
complications during pregnancy and delivery of the female sibling 2 fol-
lowing intrauterine treatmentwere reported and the infant appeared to
be healthy and without congenital anomalies. MRI of the brain after
birth showed slightly delayedwhitemattermaturation and asymmetric
increased signal intensities of thewhite layer (Table 1b). In contrast, sib-
ling 1 showed diffuse supratentoric cortical atrophy without signs of
hypoxic-ischaemic lesions and eye ﬁndings revealed bilateral loss of
photoreceptors in the central region of the macula and partial optic at-
rophy at 29 days of age (Table 1b). Data of the very different psychomo-
tor development in both siblings are shown in Table 1b. Sibling 2
attends secondary school with excellent success and has a total IQ of
103 (WISC-IV). The affected older sibling shows in theDenver test a cor-
responding development of an 8–11 months infant even treated from
4 weeks of age with OHCbl, betaine and folic acid as described [4]. For
details we refer to reference [4]. She is unable to walk, lacks speech de-
velopment and shows an aggressive behaviour which is partly con-
trolled by pipamperon and atomoxetine (Table 1c).
Biochemical results from amniotic ﬂuid at gestational week 15 as
well as postnatal serum and urine for sibling 2 are summarised in
Table 1a. Values for methylmalonic acid and homocysteine were pre-
and post-natally elevated. However, methylmalonic acid excretion
over the years remained below 60 mmol/mol creatinine (normal,
b20 mmol/mol) and serum tHcy between 40 and 60 μmol/l (reference,
b12 μmol/l).
Both affected children share the same genotype and similar residual
enzymatic activity (Table 2). Total uptake of [57Co]cyanocobalamin was
strongly reduced compared to values of 32 control individuals (Table 2).
The percentage of methylcobalamin (MeCbl) and adenosylcobalamin
(AdoCbl) was reduced in comparison to the mean control value, the
percentage of cyanocobalamin (CNCbl) was increased and the percent-
age of OHCbl was in range of the control values for both children
(Table 2).
Monitoring of serum tHcy over time shows values b100 μmol/l in
both siblings (in sibling 1 from 3 months of age, Fig. 2). However, vari-
ations in tHcy were generally higher in the girl without prenatal OHCbl
treatment.
Methylmalonic acid in urine was only slightly elevated in both sib-
lings (Table 1). Decrease of methylmalonic excretion in urine and me-
thionine concentration in serum of sibling 1 is shown in Fig. 3
indicating rapid response to the treatment in sibling 1.
4. Discussion
The high rate of congenital anomalies, including heart defects and
CNS involvement, observed in early-onset cblC defect patients suggests
that enzymatic dysfunction during embryonal and/or fetal stages of de-
velopment contribute to the clinical phenotype [1] and that postnatal
treatment alone may not be sufﬁcient to support normal psychomotor
development and prevent ocular damage [5, 6]. The outcome in our pre-
natally treated patient reported here with cblC defect was much more
favourable than in a case previously described [7], in which prenatal
treatment was initiated at a lower dose and at a later gestational stage
(2 mg/week OHCbl from week 25 compared to 30 mg/week OHCbl
from week 15 in our patient). In the case described by Huemer et al.
[7] retinopathy and cognitive impairment could not be prevented and
tHcy was highly elevated (160.9 μmol/l) in a neonate despite prenatal
treatment. Methylmalonic acid excretionwas also signiﬁcantly elevated
(393 mmol/mol creatinine). In our patient, tHcy was 27.3 μmol/l and
methylmalonic acid excretion was 66 mmol/mol creatinine after deliv-
ery, suggesting a better therapeutic effect associated with the higher
dosage of OHCbl on the fetus (Table 1a).
Both the low level of enzymatic activity and theMMACHC locus ge-
notype (c.457CNT, p.Arg153*/c.271dupA, p.Arg91Lysfs*14) suggest a
Table 1
a: Prenatal and postnatal metabolic parameters in sibling 2, treated from week 15 of ges-
tation with maternal intramuscular OHCbl (3 × 10 mg/week) and oral folic acid (5 mg/
day). b: Summary of biochemical and clinical ﬁndings in sibling 1 and 2 and c: actual
treatment.
a) Biochemical prenatal (15th week of
gestation)
and postnatal ﬁndings
Sibling 2 Normal
Propionylcarnitine in amniotic ﬂuid (13
weeks of gestation)
3.8 μmol/l 0.8–1.8 μmol/l (n = 5)
Methylmalonic acid in amniotic ﬂuid 11.7 μmol/l b0.7 μmol/l (n = 5)
Vit B12 in serum under treatment
(mother) 20 weeks of gestation
N20,000 pg/ml 160–1100 pg/ml
Homocysteine in cord blood 45.1 μmol/l b8 μmol/l
Homocysteine in serum at day 1 27.3 μmol/l b12 μmol/l
Vit B12 in serum at day 1 N20,000 pg/ml 160–1100 pg/ml
Homocysteine in serum day 7 41.7 b12 μmol/l
Propionylcarnitine in dried blood at day
1
5 b6.8
Methylmalonic acid excretion in urine at
day 7
66 mmol/mol
creatinine
0–10 mmol/mol
creatinine
b) Biochemical ﬁndings
postnatal
Sibling 1 Sibling 2 Normal
Methylmalonic acid in
urine at 20 days of age
1940 mmol (mol
creatinine)
60 mmol/mol
creatinine
0–10 mmol/mol
creatinine
Propionylcarnitine at 20
days/at day 1
32 5 b6.8
Homocysteine in serum at
20 days of age
282 μmol/l 41 b8
Actuala methylmalonic
acid in plasma
9.1 μmol/l 2.7 μmol/l b0.26 μmol/l
Actuala homocysteine
serum
Not available 72 μmol/l b8
Actuala methionine in
serum
37 μmol/l 23 μmol/l 15–45 μmol/l
Actuala methylmalonic
acid in urine
Not available 17.6 mmol/mol
creatinine
0–10 mmol/mol
creatinine
Clinical ﬁndings Sibling 1 Sibling 2
Weight at birth 2570 (1st perc.) 3100 (10th perc.)
Head
circumference at
birth
33(1st perc.) 35 (25th perc.)
General ﬁndings at
infancy/at birth
Hypotonia, feeding problems,
heart murmur at day 20,
myoclonic seizures,
horizontal nystagmus,
respiratory distress
Normal clinical ﬁndings
MRI of brain at day
29/day 7
Diffuse supratentoric cortical
atrophy without signs of
hypoxic-ischaemic lesions
Slightly delayed white matter
maturation and asymmetric
increased signal intensities of
the white layer
Actuala
development
test, IQ
Denver test corresponds to
8–11 months of age
WISC-IV total IQ 103
Actuala somatic
status
32 kg (z-score−5), height
ca. 140 cm (b3rd perc.), HC
48 cm (b3rd perc)
Height 150 cm (47th perc.),
weight 34 kg (21st perc.), HC
52.5 (9th perc.)
Ophthalmic
ﬁndings at 3
months of age
sibling 1
Bil loss of photoreceptors in
the central region of the
macula and partial optic
atrophy [4]
Not investigated
Actuala
ophthalmic
ﬁndings
Bil nystagmus, bil disc pallor,
fundi? (no cooperation)
Acuity (distance) 20/30, no
nystagmus, minor marginal
disc pallor, normal fundi
c) Actuala treatment
Hydroxycobalamin 2 × 10 mg i.m./week 2 × 10 mg i.m./week
Folic acid 5 mg/day 5 mg/day
Betaine 180 mg/kg BW/day 180 mg/kg BW/day
Pipamperon 3 × 20 mg p.o./day
Atomoxetine 1 × 18 mg p.o./day
a Actual: sibling 1: 16 years, sibling 2: 11 years of age.
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severe congenital defect in the siblings reported here. The same geno-
type has been described in several patients with early-onset cblC defect
[2, 8, 9] and no patients with this genotype and late-onset disorder have
been described. In addition, the nonsense mutation (c.457CNT,
p.Arg153*) has been described in combination with c.331CNT
(p.Arg111*) in a further early-onset patient [2] and in combination
with a missense mutation (c.365ANG, p.His122Arg) in patients with
late-onset disease [10].
The contribution of additional factors beyond prenatal treatment
that may have inﬂuenced the contrasting outcomes in the two siblings
described here cannot be excluded. A large variation in clinical symp-
toms between siblings with late-onset disease is well known [11–13].
Augoustides-Savvopoulou et al. describe a child with early-onset symp-
toms of cblC defect with severe neonatal seizures, developmental delay
and spastic paraparesis who died at the age of 13 years, while the child's
Fig. 1.A)Normally developed sibling 2 at the age of seven years (prenatal and postnatal treatment); B) severely intellectually disabled sibling 1 at the age of 12 years (postnatal treatment
only).
Table 2
Comparison of intracellular metabolic processing of CNCbl (ﬁbroblasts) in siblings with
identical genotype compared to control individuals (n=32). AdoCbl, adenosylcobalamin;
CNCbl, cyanocobalamin; MeCbl, methylcobalamin; OHCbl, hydroxycobalamin.
Patient ID 160 Patient ID 959 Control value
mean (range)
[57Co]cyanocobalamin uptake (pg/mg protein)
Total uptake 8.8 10 71 (19–142)
Cobalamin coenzyme synthesis from [57Co]cyanocobalamin (distribution of
cobalamins: % of total cobalamins)
MeCbl 3.3 1.0 60 (48–78)
AdoCbl 3.8 3.5 14 (6.9–30)
CNCbl 82 77 8.7 (3.3–18)
OHCbl 10 18 16 (7.3–25)
Fig. 2. Serum homocysteine concentration in two siblings with cblC defect from day 1 in the antenatally-treated patient (sibling 2) and in her older sister (sibling 1) whowas detected by
selective screening of organic acids in urine on day 29 [Table 2 and citation [4]].
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sibling developed apparently normally until the age of ten years, when a
decline in cognitive abilities, ataxia and myoclonic jerks occurred [14].
Also our case (sibling 1) suffered from metabolic decompensation at
3 weeks of age which may have contributed to the unfavourable devel-
opment. However, eye and cerebral MRI ﬁndings of the brain indicate
that these early changes may have developed prenatally and are not
likely to be caused by increased homocysteine levels in the ﬁrst
3weeks of life or bymetabolic decompensation. The very rapid decrease
of methylmalonic excretion in urine and normalization of plasma me-
thionine indicate the otherwise excellent reaction on OHCbl treatment
(Fig. 3). There were no different treatment modalities in both children,
however, there is someuncertainty about a “safe” level of homocysteine
in respect to an impact on the neurologic development. There are no
long term prospective studies from birth showing the inﬂuence of ele-
vated homocysteine on the psychomotoric/ocular development [6].
In conclusion, this very limited experience suggests that early prena-
tal treatment may prevent disease manifestations in patients at risk of
developing a cblC defect phenotype.With successful newborn screening
the possibility of improving outcome in patients with cblC defect has al-
ready been established [5, 15, 16], however prenatal diagnosis and
treatment together with lifelong postnatal treatment may represent
an opportunity to prevent the manifestation of clinical symptoms alto-
gether. Our results suggest that intrauterine treatment should be initiat-
ed as early as possible in an affected fetus and continued throughout
gestation. The high dosage used here resulted in a high Vit B12 concen-
tration in the mother's as well as in the fetal blood circulation as docu-
mented at day 1 of life. The importance of high OHCbl dosages to
reduce homocysteine andmethylmalonic acid have been demonstrated
in a 13 year old patient [17]. Further experiences in similar cases during
pregnancy should be collected in the future and Vit B12 and postnatal
homocysteine levels should be monitored closely in affected patients
to better understand the impact of OHCbl dosage on homocysteine
levels in serum [18].
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